FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer

doi:10.5306/wjco.v9.i5.110

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6069)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

482

WORD

208

HTML

2866

Figures (1-3)

180

Tables (1-4)

152

Sum=3888

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

941

Download

1240

Sum=2181

Sep 14, 2018 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Sep 14, 2018; 9(5): 110-118
Published online Sep 14, 2018. doi: 10.5306/wjco.v9.i5.110

Full Size Figure Download Figure

Figure 1 Comparison of the FOLFIRI-1and FOLFIRI-3 schedules.

Citation: Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, Gramont A, Chibaudel B. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol 2018; 9(5): 110-118
URL: https://www.wjgnet.com/2218-4333/full/v9/i5/110.htm
DOI: https://dx.doi.org/10.5306/wjco.v9.i5.110